Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Valeant reports results of study

Valeant reports results of study

28th November 2008

Valeant has reported the results of an end of treatment, week 48 analysis point in a Phase IIb clinical trial.

The research into the antiviral compound taribavirin – a pro-drug of ribavirin – saw comparable reductions in viral load for weight-based doses of the products, with the anaemia rate lower for patients receiving the former.

Research saw a group of 278 treatment-naive, genotype 1 patients with a mean age of 48.8 years old, a viral load of 400,000 IU/mL and an average weight of 82.1 kg.

Of the patients, 61.1 percent were males and 30 per cent were of African-American or Latino origin.

The drug is in development for the treatment of chronic hepatitis C, in conjunction with a pegylated interferon.

Fred Poordad, managing director and chief of Hepatology at the Centre for Liver Disease and Transplantation at the Cedars-Sinai Medical Centre in Los Angeles, US, said: “The results of this phase II study are encouraging and suggest that comparable efficacy on therapy can be achieved when compared to ribavirin.”

He added that if the sustained response rates are similar with less anaemia, it will be “a significant step forward in the development of taribavirin.”

Founded in 1960, Valeant employs approximately 2,600 people.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.